Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | DRD4 | P21917 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | ADAMTS5 | Q9UNA0 | 3/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3546173 | 0.88 | DRD2 (0.51) | DRD2DRD4DRD3ALDH1A1TSHR | |
| SCHEMBL3551183 | 0.85 | ALDH1A1 (0.61) | DRD2DRD4DRD3ALDH1A1TSHR | |
| SCHEMBL3551695 | 0.79 | FFAR4 (0.48) | DRD2DRD4DRD3ALDH1A1TSHR | |
| SCHEMBL3550856 | 0.78 | HTR7 (0.51) | DRD2DRD3HTTKMT2A | |
| SCHEMBL3436299 | 0.77 | ALDH1A1 (0.51) | DRD2DRD4DRD3ALDH1A1TSHR | |
| SCHEMBL4687057 | 0.77 | DRD2 (0.56) | DRD2DRD4DRD3ALDH1A1MEN1 | |
| SCHEMBL16387109 | 0.76 | ALDH1A1 (0.62) | DRD2DRD4DRD3ALDH1A1HTT | |
| SCHEMBL3553897 | 0.76 | IGF1R (0.53) | DRD2DRD4ALDH1A1TSHRHTT | |
| SCHEMBL23717773 | 0.76 | ALDH1A1 (0.53) | ALDH1A1TSHRHTTMEN1KMT2A | |
| SCHEMBL22400161 | 0.76 | ALDH1A1 (0.49) | DRD2DRD4DRD3ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | DRD2 3571/4885DRD4 4535/4885DRD3 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.